Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-18871
Ladogana, A; Sanchez-Juan, P; Mitrová, E; Green, A; Cuadrado-Corrales, N; Sánchez-Valle, R; Koscova, S; Aguzzi, A; Sklaviadis, T; Kulczycki, J; Gawinecka, J; Saiz, A; Calero-Lara, M; van Duijn, C M; Pocchiari, M; Knight, R; Zerr, I (2009). Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. Journal of Neurology, Epub a:1-9.
|PDF - Registered users only|
The 14-3-3 protein test has been shown to support the clinical diagnosis of sporadic Creutzfeldt-Jakob disease (CJD) when associated with an adequate clinical context, and a high differential potential for the diagnosis of sporadic CJD has been attributed to other cerebrospinal fluid (CSF) proteins such as tau protein, S100b and neuron specific enolase (NSE). So far there has been only limited information available about biochemical markers in genetic transmissible spongiform encephalopathies (gTSE), although they represent 10-15% of human TSEs. In this study, we analyzed CSF of 174 patients with gTSEs for 14-3-3 (n = 166), tau protein (n = 78), S100b (n = 46) and NSE (n = 50). Levels of brain-derived proteins in CSF varied in different forms of gTSE. Biomarkers were found positive in the majority of gCJD (81%) and insert gTSE (69%), while they were negative in most cases of fatal familial insomnia (13%) and Gerstmann-Sträussler-Scheinker syndrome (10%). Disease duration and codon 129 genotype influence the findings in a different way than in sporadic CJD.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Neuropathology|
|DDC:||570 Life sciences; biology|
610 Medicine & health
|Date:||15 May 2009|
|Deposited On:||08 Jun 2009 10:00|
|Last Modified:||23 Nov 2012 15:17|
|Additional Information:||SpringerLink – Full text article|
|WoS Citation Count:||9|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page